Active Ingredient History
Vandetanib, 4-anilinoquinazoline, is an anti-cancer drug that with the potential for use in a broad range of tumour types. In 2011 vandetanib (trade name Caprelsa) was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. In vitro studies have shown that vandetanib inhibits the tyrosine kinase activity of the EGFR and VEGFR families, RET, BRK, TIE2, and members of the EPH receptor and Src kinase families. These receptor tyrosine kinases are involved in both normal cellular function and pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, and maintenance of the tumor microenvironment. Vandetanib was shown to inhibit epidermal growth factor (EGF)-stimulated receptor tyrosine kinase phosphorylation in tumor cells and endothelial cells and VEGF-stimulated tyrosine kinase phosphorylation in endothelial cells. Vandetanib administration reduced tumor cell-induced angiogenesis, tumor vessel permeability, and inhibited tumor growth and metastasis in mouse models of cancer. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Adenocarcinoma (Phase 1)
Astrocytoma (Phase 2)
Bile Duct Neoplasms (Phase 2)
Biliary Tract Neoplasms (Phase 2)
Brain Neoplasms (Phase 1)
Breast Neoplasms (Phase 2)
Carcinoma (Phase 2)
Carcinoma, Hepatocellular (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Carcinoma, Renal Cell (Phase 2)
Carcinoma, Transitional Cell (Phase 2)
Carcinoma, Verrucous (Phase 2)
Colonic Neoplasms (Phase 1)
Colorectal Neoplasms (Phase 2)
Diffuse Intrinsic Pontine Glioma (Phase 1)
Esophageal Neoplasms (Phase 1)
Fallopian Tube Neoplasms (Phase 2)
Gallbladder Neoplasms (Phase 2)
Gastrointestinal Stromal Tumors (Phase 2)
Glioblastoma (Phase 2)
Glioma (Phase 1)
Gliosarcoma (Phase 2)
Hamartoma (Phase 2)
Head and Neck Neoplasms (Phase 2)
Healthy Volunteers (Phase 1)
Hormones (Phase 2)
Intestinal Neoplasms (Phase 1)
Kidney Neoplasms (Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Lung Neoplasms (Phase 3)
Lymphoma (Phase 1)
Lymphoproliferative Disorders (Phase 1)
Mesothelioma (Phase 2)
Multiple Endocrine Neoplasia Type 2a (Phase 1/Phase 2)
Multiple Endocrine Neoplasia Type 2b (Phase 1/Phase 2)
Multiple Myeloma (Phase 2)
Myoma (Phase 1/Phase 2)
Neoplasm Metastasis (Phase 2)
Neoplasms ()
Neuroblastoma (Phase 1)
Oligodendroglioma (Phase 2)
Ovarian Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 2)
Paraganglioma (Phase 1)
Peritoneal Neoplasms (Phase 2)
Pleural Effusion (Phase 2)
Precancerous Conditions (Phase 2)
Prostatic Neoplasms (Phase 2)
Small Cell Lung Carcinoma (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Stomach Neoplasms (Phase 2)
Thyroid Cancer, Papillary (Phase 2)
Ureteral Neoplasms (Phase 2)
Urethral Neoplasms (Phase 2)
Urinary Bladder Neoplasms (Phase 2)
von Hippel-Lindau Disease (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
